Low-Dose Acetazolamide in the Treatment of Premenstrual Dysphoric Disorder: A Case Series
Psychiatry Investigation
;
: 95-101, 2014.
Artículo
en Inglés
| WPRIM
| ID: wpr-173014
ABSTRACT
The treatment of premenstrual dysphoric disorder (PMDD) is far from satisfactory, as there is a high proportion of patients who do not respond to conventional treatment. The antidiuretic sulfonamide, acetazolamide, inhibits carbonic anhydrase and potentiates GABAergic transmission; the latter is putatively involved in PMDD. We therefore tried acetazolamide in a series of women with intractable PMDD. Here, we describe a series of eight women diagnosed with DSM-IV-TR PMDD, five of whom had comorbidity with a mood disorder and one with an anxiety disorder, who were resistant to treatment and responded with symptom disappearance after being added-on 125 mg/day acetazolamide for 7-10 days prior to menses each month. Patients were free from premenstrual symptoms at the 12-month follow-up. We suggest that acetazolamide may be used to improve symptoms of PMDD in cases not responding to other treatments. GABAergic mechanisms may be involved in counteracting PMDD symptoms.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Trastornos de Ansiedad
/
Comorbilidad
/
Estudios de Seguimiento
/
Anhidrasas Carbónicas
/
Trastornos del Humor
/
Acetazolamida
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Psychiatry Investigation
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS